What does the evidence say about Vitamin K2 Bone Markers Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K2 Bone Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background Osteoporosis is a metabolic bone disease characterized by decreased bone mass and increased fracture risk. [Zhang Z (2025); evidence level 1] - Vitamin K2 (VK2) increased osteocalcin (OC; MD 1.86, 95% CI 1.17-2.56) and bone-specific alkaline phosphatase (BAP; MD 1.49, 95% CI 0.98-2.00). [Zhang Z (2025); evidence level 1] - It reduced undercarboxylated OC (ucOC; WMD -1.54, 95% CI -2.44 to -0.64) and tartrate-resistant acid phosphatase (TRAP; MD -0.83, 95% CI -1.21 to -0.46). [Zhang Z (2025); evidence level 1] - Bone turnover markers, such as osteocalcin (OC), undercarboxylated osteocalcin (ucOC), and other biochemical indicators, are important for assessing bone metabolism. [Zhang Z (2025); evidence level 1] - Conclusions : These findings identify vitamin K-dependent carboxylation as a mechanistically specific and modifiable factor associated with skeletal fragility beyond bone mineral density, with distinct skeletal consequences across osteocalcin carboxylation states. [Sharma DK (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.